The IVNS1ABP Knockout HeLa Polyclonal Cells are a pooled population of HeLa cells that have undergone CRISPR/Cas9-mediated disruption of the IVNS1ABP locus, resulting in a heterogeneous loss-of-function model. This polyclonal knockout format retains genetic diversity within the population, enabling robust population-based assays while minimizing the risk of clonal selection bias. The product is designed for researchers seeking to interrogate IVNS1ABP function in antiviral innate immunity and actin cytoskeleton dynamics.
HeLa is an immortalized human cervical adenocarcinoma cell line with epithelial characteristics, widely used in cancer biology and virology. HeLa cells support productive influenza A virus infection and offer a well-characterized system for investigating signaling pathways and cytoskeletal organization. Their vigorous growth and experimental tractability make them an optimal host for knockout studies targeting innate immunity and tumor cell migration.
IVNS1ABP negatively regulates antiviral innate immunity by interacting with TRAF3 and inhibiting IRF3 activation, thereby suppressing the RIG-I/MAVS/TRAF3/TBK1 signaling cascade and downstream NF-??B responses. The protein also binds the influenza A NS1 protein, an interaction that enhances viral replication by subverting host defenses. Concurrently, IVNS1ABP stabilizes actin stress fibers via its Kelch-repeat domains, linking immune signaling to cytoskeletal architecture. IVNS1ABP expression is induced by type I interferons and activated by viral RNA sensors such as RIG-I and TLRs, placing it at a critical node of pathogen detection and signal transduction.
In the HeLa cervical adenocarcinoma background, IVNS1ABP knockout enables dissection of how this factor coordinates immune evasion with actin-dependent processes like cell migration and invasion. The model is particularly valuable for influenza research, as loss of IVNS1ABP may relieve inhibition of IRF3, augmenting antiviral gene expression and providing a tool to study NS1-mediated immunomodulation. Furthermore, destabilization of actin stress fibers upon IVNS1ABP disruption offers insights into epithelial-to-mesenchymal transition and metastatic behavior.
Researchers can apply this polyclonal knockout model in co-immunoprecipitation studies of IVNS1ABP complexes with TRAF3 or NS1, Western blotting for IRF3 phosphorylation, and luciferase reporter assays for IFN?? induction. Functional assays include influenza viral replication kinetics, wound healing, and Transwell migration tests, coupling antiviral immunity readouts with cytoskeletal dynamics. This versatile tool advances investigations in host?Cpathogen interaction biology, cancer cell motility, and innate immune regulation. For further information, contact Ascent Research.
